Overview

Efficacy and Tolerability of the Combination of Valproic Acid and Lenalidomide in the Treatment of Patients With Myelodysplastic Syndrome

Status:
Terminated

Trial end date:
2014-05-01

Target enrollment:

Participant gender:

Summary

As part of a palliative therapy concept, feasibility, toxicity, and effectiveness of treatment with the combination of Valproic acid and lenalidomide in Myelodysplastic Syndrome patients with a favorable risk profile will be investigated.

Phase:

Phase 2

Details

Lead Sponsor:

Heinrich-Heine University, Duesseldorf

Treatments:

Lenalidomide
Thalidomide
Valproic Acid